Clinical research: interventional cardiology
Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: Serial intravascular ultrasound analysis from the sirius trial

https://doi.org/10.1016/j.jacc.2004.01.044Get rights and content
Under an Elsevier user license
open archive

Abstract

Objectives

We assessed the predictive value of minimum stent area (MSA) for long-term patency of sirolimus-eluting stents (SES) implantation compared to bare metal stents (BMS).

Background

Although MSA is a consistent predictor of in-stent restenosis, its predictive value in BMS is still limited because of biologic variability in the restenosis process.

Methods

From the SIRolImUS (SIRIUS) trial, 122 cases (SES: 72; BMS: 50) with complete serial intravascular ultrasound (IVUS) (baseline and 8-month follow-up) were analyzed. Postprocedure MSA and follow-up minimum lumen area (MLA) were obtained. Based on previous physiologic studies, adequate stent patency at follow-up was defined as MLA >4 mm2.

Results

In both groups, a significant positive correlation was observed between baseline MSA and follow-up MLA (SES: p < 0.0001, BMS: p < 0.0001). However, SES showed higher correlation than BMS (0.8 vs. 0.65) with a higher regression coefficient (0.92 vs. 0.59). The sensitivity and specificity curves identified different optimal thresholds of MSA to predict adequate follow-up MLA: 5 mm2for SES and 6.5 mm2for BMS. The positive predictive values with these cutoff points were 90% and 56%, respectively.

Conclusions

In this SIRIUS IVUS substudy, SES reduced both biologic variability and restenosis, resulting in increased predictability of long-term stent patency with postprocedure MSA. In addition, SES had a considerably lower optimal MSA threshold compared to BMS.

Abbreviations

BMS
bare metal stents
IVUS
intravascular ultrasound
MLA
minimum lumen area
MSA
minimum stent area
SES
sirolimus-eluting stents

Cited by (0)

Dr. Sonoda is supported by Fukuda Memorial Foundation for Medical Technologies, Tokyo, Japan and Japan North America Medical Exchange Foundation, Tokyo, Japan. Dr. Yock: grant, stock shareholder (Johnson and Johnson); Dr. Leon: stock shareholder (Johnson and Johnson); Dr. Moses: consultant, stock shareholder (Johnson and Johnson); Dr. Fitzgerald: consultant (Cordis, Johnson and Johnson).